[Swallowable gastric balloon in obesity]

Lazo E, Bardach A, Navarro E, Alfie V, Ciapponi A, Pichon Riviere A, García Martí S, Alcaraz A, Augustovski F
Record ID 32018004426
Spanish
Original Title: Balón intragástrico deglutible en obesidad
Authors' recomendations: Very low-quality evidence does not allow to draw conclusions on the effectiveness or safety of the Allurion® gastric balloon for the treatment of adults with obesity. Low-quality evidence suggests that the Allurion® gastric balloon may result in a lower net benefit in adults with obesity requiring preoperative weight loss as a transition towards bariatric surgery since, although it results in a total body weight loss (estimated at approximately 12 %); this is short-term and transient. In addition, adverse effects were uncommon but potentially serious, if present. The studies available are based on patients with Grade I and II obesity. No evidence assessing its efficacy and/or safety versus pharmacological therapy, bariatric surgery or other gastric balloon models has been found. Only one clinical practice guideline mentions this swallowable balloon and supports its use in ight at short term due to medical reasons, explaining its potential adverse effects in detail. One economic evaluation that includes international data (mainly from Western Europe) found that the balloon may be cost-saving and improve health outcomes if used as a transition towards bariatric surgery. From that perspective and in that region, it has been cost-effective as treatment in patients who do not have access or are not willing to undergo surgery. In Argentina, the balloon is not part of the therapeutic strategies included in Law 26,396, which regulates coverage for eating disorders, or the Mandatory Medical Program.
Details
Project Status: Completed
Year Published: 2022
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Obesity
  • Obesity Management
  • Weight Loss
  • Gastric Balloon
  • Obesity, Morbid
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.